Bavarian To Buy Emergent BioSolutions Vaccines For $380M
Danish biotechnology company Bavarian Nordic AS said Wednesday it will acquire three travel vaccines and related assets from U.S. rival Emergent BioSolutions Inc. for $380 million, in a deal guided by...To view the full article, register now.
Already a subscriber? Click here to view full article